The glutathione system: a new drug target in neuroimmune disorders.
Morris, Gerwyn, Anderson, George, Dean, Olivia et al. · Molecular neurobiology · 2014 · DOI
Quick Summary
This review examines glutathione (GSH), a naturally occurring substance in our cells that protects against damage and helps our immune system work properly. When glutathione levels drop, cells become more stressed and inflamed, which may contribute to ME/CFS and other conditions affecting the brain and immune system. The authors suggest several potential treatments—including supplements like N-acetyl cysteine and natural compounds like curcumin—that might help restore glutathione levels.
Why It Matters
For ME/CFS patients, this work provides a unifying biochemical mechanism that could explain multiple disease features: energy dysfunction, immune dysregulation, and neurological symptoms. If GSH depletion is indeed central to ME/CFS pathology, it opens the door to testable therapeutic approaches and identifies specific biological targets for drug development.
Observed Findings
Glutathione depletion correlates with increased oxidative and nitrosative stress (ROS/RNS) and inflammatory mediators in various disease states
GSH acts as an essential cofactor for antioxidant enzymes (glutathione peroxidases, GSH S-transferases) that detoxify harmful molecules
GSH dysfunction disrupts key intracellular signaling pathways including NF-κB, p53, and Janus kinases
GSH depletion impairs mitochondrial complex I function and can trigger apoptosis
GSH depletion compromises T cell activation and immune system homeostasis
Inferred Conclusions
GSH depletion is a mechanistic link between oxidative stress, mitochondrial dysfunction, and immune dysregulation in neuroimmune diseases including ME/CFS
Therapeutic strategies to restore GSH—including N-acetyl cysteine, Nrf-2 activation, and phytochemicals—warrant clinical investigation in ME/CFS
GSH restoration may address multiple disease pathways simultaneously, affecting energy metabolism, inflammation, and neurological function
Remaining Questions
Are glutathione levels actually depleted in ME/CFS patients compared to healthy controls, and does depletion severity correlate with symptom severity?
Which GSH-restoring intervention (NAC, curcumin, dimethyl fumarate, etc.) is most effective and bioavailable in ME/CFS, and at what doses?
What This Study Does Not Prove
This review does not prove that GSH depletion causes ME/CFS or that GSH-restoring therapies will effectively treat the disease. It presents correlational evidence and mechanistic reasoning rather than clinical trial data. Direct measurement of GSH levels in ME/CFS patients and controlled trials of proposed interventions remain necessary.
Do patients with ME/CFS show the predicted signs of GSH depletion (elevated ROS/RNS markers, mitochondrial dysfunction) that would validate this mechanistic model?
Can GSH restoration interventions improve clinical outcomes in randomized controlled trials of ME/CFS patients?